Lexicon New Alzheimer's Disease Trial Dosing (LXRX)

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that dosing has commenced in its Phase IIa clinical trial with LX6171.  This is an oral drug candidate that is implied for the treatment of cognitive impairment disorders such as Alzheimer’s disease, schizophrenia, and vascular dementia.

The initial stage of the trial will assess the bioavailability of a new oral-suspension formulation in healthy elderly subjects with a second stage evaluating safety, tolerability and cognitive effects in elderly subjects with age-associated memory impairment.

This was issued ahead of its R&D webcast at Noon EST today.  Shares have not traded in pre-market trading and closed at $3.20 yesterday; its 52-week trading range is $2.80 to $4.40.

Jon C. Ogg
December 5, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.